# HER2 TREAT Study: Retrospective Study to Estimate the Prevalence of HER2-low in Unresectable and/or Metastatic Breast Cancer Patients Who Progress on Anti-Cancer Therapy Identified as HER2-Negative From Patient Medical Records in The Gulf Cooperation Council

> **NCT06125314** · — · COMPLETED · sponsor: **AstraZeneca** · enrollment: 517 (actual)

## Conditions studied

- Breast Neoplasms
- Breast Cancer
- Breast Carcinoma
- Genes
- HER2

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT06125314
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2024-03-05
- **Primary completion:** 2024-09-30
- **Final completion:** 2024-09-30
- **Target enrollment:** 517 (ACTUAL)
- **Last updated:** 2025-09-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06125314

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06125314, "HER2 TREAT Study: Retrospective Study to Estimate the Prevalence of HER2-low in Unresectable and/or Metastatic Breast Cancer Patients Who Progress on Anti-Cancer Therapy Identified as HER2-Negative From Patient Medical Records in The Gulf Cooperation Council". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06125314. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*